1. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)–1
- Author
-
Agrawal, R., Gunasekeran, D. V., Grant, R., Agarwal, A., Kon, O. M., Nguyen, Q. D., Pavesio, C., Gupta, V., Gupta, B., Aggarwal, K., Murthy, S. L., Westcott, M., Phaik, C. S., Mccluskey, P., Ling, H. S., Teoh, S., Cimino, L., Biswas, J., Narain, S., Agarwal, M., Mahendradas, P., Khairallah, M., Jones, N., Tugal-Tutkun, I., Babu, K., Basu, S., Carreno, E., Lee, R., Al-Dhibi, H., Bodaghi, B., Invernizzi, A., Goldstein, D. A., Herbort, C. P., Barisani, T., Gonzalez-Lopez, J. J., Androudi, S., Bansal, R., Moharana, B., Mahajan, S., Esposti, S., Tasiopoulou, A., Nadarajah, S., Abraham, S., Vala, R., Singh, R., Sharma, A., Sharma, K., Zierhut, M., Raje, D., Cunningham, E., and Kempen, J.
- Subjects
medicine.medical_specialty ,Tuberculosis ,POLYMERASE-CHAIN-REACTION ,DIAGNOSIS ,DISEASE ,LATENT TUBERCULOSIS ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,SERPIGINOUS-LIKE CHOROIDITIS ,INTRAOCULAR TUBERCULOSIS ,MANAGEMENT ,medicine ,030212 general & internal medicine ,RETINAL VASCULITIS ,Science & Technology ,Latent tuberculosis ,business.industry ,Retinal vasculitis ,Collaborative Ocular Tuberculosis Study (COTS)–1 Study Group ,Hazard ratio ,Panuveitis ,Retrospective cohort study ,GLOBAL BURDEN ,medicine.disease ,Surgery ,ANTERIOR UVEITIS ,Ophthalmology ,030221 ophthalmology & optometry ,Intermediate uveitis ,business ,Life Sciences & Biomedicine ,Uveitis - Abstract
Importance Eradication of systemic tuberculosis (TB) has been limited by neglected populations and the HIV pandemic. Whereas ocular TB often presents as uveitis without any prior evidence of systemic TB, the existing uncertainty in the diagnosis of TB uveitis may perpetuate missed opportunities to address systemic TB. Objective To examine the clinical features of TB uveitis and the associations with response to antitubercular therapy (ATT). Design, Setting, and Participants This retrospective multinational cohort study included patients from 25 ophthalmology referral centers diagnosed with TB uveitis and treated with ATT from January 1, 2004, through December 31, 2014, with a minimum follow-up of 1 year. Main Outcomes and Measures Treatment failure, defined as a persistence or recurrence of inflammation within 6 months of completing ATT, inability to taper oral corticosteroids to less than 10 mg/d or topical corticosteroid drops to less than 2 drops daily, and/or recalcitrant inflammation necessitating corticosteroid-sparing immunosuppressive therapy. Results A total of 801 patients (1272 eyes) were studied (mean [SD] age, 40.5 [14.8] years; 413 [51.6%] male and 388 [48.4%] female; 577 [73.6%] Asian). Most patients had no known history (498 of 661 [75.3%]) of systemic TB. Most patients had bilateral involvement (471 of 801 [58.8%]). Common clinical signs reported include vitreous haze (523 of 1153 [45.4%]), retinal vasculitis (374 of 874 [42.8%]), and choroidal involvement (419 of 651 [64.4%]). Treatment failure developed in 102 of the 801 patients (12.7%). On univariate regression analysis, the hazard ratios (HRs) associated with intermediate uveitis (HR, 2.21; 95% CI, 1.07-4.55; P = .03), anterior uveitis (HR, 2.68; 95% CI, 1.32-2.35; P = .006), and panuveitis (HR, 3.28; 95% CI, 1.89-5.67; P
- Published
- 2017
- Full Text
- View/download PDF